Clinical Trial Search

Primary: Change in Macular Drusen Volume — 0.05; 0.11; 20.0; 9.0 mm^3

Primary: Development of Advanced AMD in People at Moderate to High Risk for Progression. — 493; 468; 507; 472 Eyes — p=<0.013

Primary: The Change in Best-corrected Visual Acuity (BCVA) From Baseline to Year 2 for All Participants. — 0.2; -11.3 ETDRS Letters

Primary: Mean Change From Baseline in Visual Acuity — 1.8; 1.0 ETDRS letters

Primary: Growth of Geographic Atrophy — 0.18; 0.19 millimeters

Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…

Primary: BCVA Response Defined as an Increased in 10 Letters at 1 Year Post-implant — 3; 3; 1; 9 eyes

Primary: Changes of Macular Pigment Optical Density (MPOD) During 48 Weeks and 2 Years — 0.315; 0.307; 0.315; 0.320 density units — p=<0.05

Primary: Rate of Change in Area of Geographic Atrophy (GA), Based on Masked, Digital Grading of Fundus Photography by an External Reading Center, in the Study Eye at 12 Months…

Primary: Mean Change in Visual Acuity — 15.0; 5.6 letters — p=0.02

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Monthly Rates of Anti-VEGF (Vascular Endothelial Growth Factor) Injections — 0.42; 0.83; 0.34; 0.83 Injections per Month

Primary: The Number of Patients With no Fluid on OCT — 10 participants

Primary: Change in Dark Adaptation Rod Intercept Time (RIT) From Baseline in the Study Eye at the Treatment Completion Visit (Month 2 for Cohort 1 and Month 1 for Cohort 2)…

Primary: Macular Pigment Optical Density — 0.48; 0.38; 0.42 Density units of Macular Pigment (du)

Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…

Primary: Number of Participant With Improvement in Foveal Thickness (Macular Fluid) as Measured by Optical Coherence Tomography (OCT) — 36 participants

Primary: LL BCVA Score Change From Baseline — 0.7; -0.6; 1.1; -0.8 Letters

Primary: Change in Central Subfield Thickness From Baseline at 12 Months — -50.3 µm — p=<0.001

Primary: Incidence and Severity of Ocular Adverse Events (AEs) — 1; 3; 2; 1 participants

Primary: Targeted Vision Function (TVF) — 2.18; 2.14 units on a scale — p=.47

Primary: Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24 — 0.024; 0.050; 0.363; 0.285 mm — p=0.236

Primary: Visual Acuity - Continuous — -6.1; -1.6; 2.4 Letters seen

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read

Primary: Depression — 11; 18; 5; 11 participants — p=.067

Primary: Highest Tolerated Dose (HTD) of AGN-150998 — 4.2 mg

Primary: Summary of Adverse Events — 57; 16; 47; 4 participants

Primary: Change From Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA) — 0.810; 0.526; 2.762; 1.833 letters

Primary: Number of Participants With Toxicity or Intolerable Dose Criteria — 0; 0; 0; 0 Participants

Primary: Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) — 40; 7; 33 participants